摘要
[目的]观察苦参碱联合甘利欣注射液对慢性乙型肝炎(乙肝)肝纤维化的影响。[方法]将136例慢性乙肝患者随机分为2组,治疗组72例采用苦参碱联合甘利欣注射液治疗,对照组64例采用拉米夫定治疗,6个月后观察2组患者肝功能、乙肝病毒(HBV)标志物以及肝纤维化4项指标的变化。[结果]与治疗前相比,2组均能显著降低血清丙氨酸氨基转移酶(ALT)、天冬氨酸转氨酶(AST)、透明质酸(HA)、Ⅲ型前胶原肽(PCⅢ)、层黏连蛋白(LN)、Ⅳ型胶原(Ⅳ-C),提高清蛋白/球蛋白比值(A/G)(均P<0.01);在降低ALT、AST、HA、PCⅢ、Ⅳ-C方面,治疗组明显优于对照组(P<0.05);对照组HBV DNA阴转率高于治疗组(P<0.05),治疗组HBeAg阴转率优于对照组(P<0.01)。[结论]苦参碱联合甘利欣注射液可抑制慢性乙肝肝纤维化,同时还可抑制HBV复制,促进HBV复制标志物阴转,降低转氨酶,改善肝功能。
[Objective]To observe the effect of sophocarpidine and diammonium glycyrrhizinate injection on hepatic fibrosis of chronicity type B hepatitis patients.[Methods]One hundred and thirty-six cases patients with chronicity type B hepatitis were devided into two groups at random;The treatment group（n=72）were treated by sophocarpidine and diammonium glycyrrhizinate injection,and control group（n=64） were treated by Lamivudine tablet,with one treatment period of 6 months;Liver function,type B hepatovirus marker,and hepatic fibrosis index were measured after treatment.[Results]Compared with pre-treatment,the content of alanine aminotransferase（ALT）,aspartate amino transferase（AST）,hyaluronic acid（HA）,precollagen Ⅲ（PCⅢ）,laminin（LN） and collogen Ⅳ（Ⅳ-C） in blood plasma were increased,and the ratio of albumin and globulin（A/G）were decreased obviously in two groups（P〈0.01）;compared with control group,the ALT、AST、HA、PCⅢ and Ⅳ-c were different obviously in treatment groups（P〈0.05）.the rate of HBV-DNA negative in control group surpass treatment group（P〈0.05）;the rate of HBeAg negative in treatment group surpass control groups（P〈0.01）.[Conclusion]Sophocarpidine and diammonium glycyrrhizinate injection could decrease the content of aminotransferase,restrain hepatic fibrosis and virus replication,improve the rate of HBV-DNA negative and liver function.
出处
《中国中西医结合消化杂志》
CAS
2010年第1期34-36,共3页
Chinese Journal of Integrated Traditional and Western Medicine on Digestion
关键词
乙型肝炎
慢性
肝纤维化
苦参碱注射液
甘利欣注射液
chronicity type B hepatitis
hepatic fibrosis
sophorcarpidine injection
diammonium glycyrrhizinate injection
